Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
2011-10-12
- "Following our successful fundraising in June, we are delighted to have now treated the first patients in the AEGIS Phase 3 programme and we remain on course to have top line results from these studies in late 2012. Effective treatment of IDA represents a very attractive commercial opportunity and the start of recruitment is an important milestone for Shield Therapeutics as we continue the rapid development of ST10 to address this significant unmet need for the many patients with IDA." said Carl Sterritt, Chief Executive Officer and Co-Founder of Shield Therapeutics.
Shield Therapeutics Raises 8.2 million
2011-06-01
- The investment by Inventages follows the recent completion of a final private investor led fundraising and was made at a post-money valuation of €35m (CHF43m/US$51m). The investment is scheduled in two equal tranches over the next two years. Prior to the investment by Inventages, Shield Therapeutics successfully completed three private investment rounds, raising a total of approximately €6 million (CHF7.5m/US$9.0m). The new investment will help fund the Phase III pivotal development programme and subsequent filing of a marketing authorisation.
Carl Sterritt, Shield Therapeutics:"Inventages provided the investment partnership we were looking for."
